15.Radiation survival and colony size of human epidermal keratinocytes in the presence of keratinocyte growth factor (rhKGF)  by Slonina, D. & Dörr, W.
14.
SEARCH FOR IMPROVEMENT OF
THE THERAPEUTIC RATIO IN
RADIOTHERAPY FOR NON-SMAll
CEll lUNG CANCER (NSClC)
L. Kępka*, J. Fijuth*, A. Żółciak*,
D. Blatkiewicz#, A. Ciarcińska#,W. Bulski#
*Department ot Radiation Oneology and #
Medieal Physies Department, The M.
Sklodowska-Curie Cancer Center and Institute
ot Oneology, Warsaw, Poland
There are several approaches under
investigation in view ot improvement ot the
therapeutic ratio ot NSCLC radiotherapy in our
Department:
1/ Dose escalation above 70 Gy using
contormal radiotherapy techniques, 2/
aecelerated radiotherapy with or without
induction chemotherapy addressed to III stage
tumours, 3/ contormal postoperative
radiotherapy to total minimum dose in PTV ot 50
Gy addressed to eompletely reseeted III stage
tumours.
Ad 1/ From XI 1998 to XI 2000 43 patients
were included in dose escalation study. Doses
trom 70 to 74 Gy were delivered. Apart trom one
toxie death, due to radiation pneumonitis,
toxieity was aeceptable. Sinee 1999 tor NO
patients the study ot omission ot elective
irradiation is eondueted. By the time being 10
patients were irradiated with omission ot elective
fields. There was no relapse in non-treated
"elective areas". The aetuarial 1-, 2- and 3-year
survival were respectively 84-, 64-, and 42%.
There were 14 local relapses in 19 progressions"
observed in the entire group. In spite of
encouraging results a high level of local
relapses shows the limits ot moderate dose
escalation using eonformai teehniques and
conventional fractionation in improvement of
local control ot NSCLC.
Ad 2/ From III 1999 two different accelerated
radiation therapy sehedules are investigated for
III stage tumours. Forty patients were enrolled in
the study: 26 were irradiated aceording to
accelerated hyperfraetionated radiotherapy (57
Gy in 40 fractions [first week: elective fields - 1.2
Gy x 2 per day, 3 remaining weeks 1.8 Gy to
elective tields and 1.2 Gy boost to tumour]
during 26 days), 14 were irradiated according to
accelerated conformal radiotherapy with
concurrent boost (56.7 Gy in 21 tractions and 26
days: all treatment was eonformally planned and
delivered: 1,9 Gy per fraction to the Iimited
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elective tield and 0.8 Gy as a concurrent boost
to the GTV). There was no difference on
compliance with treatment plan, toxicity and
response rate (80- and 72%) in the both
investigated groups.
Ad 3/ From I 1999 eleven patients were
enrolled in the phase II study of postoperative
contormal radiotherapy ot the region ot the
highest probability of microscopic invasion by
the disease to the minimum dose ot 50 Gy in
PTV. The study is conducted in view ot the
tuture design ot randomised study addressing
question of the value ot postoperative
radiotherapy using modern techniques in
management ot NSCLC.
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RADlATlON SURVIVAl AND COlONY
SIZE OF HUMAN EPIDERMAL
KERATINOCYTES IN THE PRESENCE
OF KERATINOCYTE GROWTH
FACTOR (rhKGF)
D. Slonina, W. Dorr
Centre ot Oncology, Kraków, Poland, Medical
Faeulty Carl Gustav Carus, Technical University,
Dresden, Germany
The capacity of recombinant human
keratinocyte growth tactor (rhKGF) to ameliorate
the radiation response ot mouse oral mucosa
and other epithelial tissues was recently
reported. However, the exact mechanisms of
action of KGF remain unclear. The aim of the
present study was to investigate the effect of
rhKGF on survival and colony size ot normai
human epidermal keratinoeytes in vitro. Primary
human neonatal keratinoeytes (HEKn) were
irradiated with doses ot O Gy and 2 Gy (200 kV
X-rays) and incubated in the presence or
absence of 100ng/ml rhKGF. Plating efficiency
(PE) and surviving traction (SF2) were
determined in a clonogenic assay. In celi
cultures without rhKGF the mean PE was 4.6%.
Irradiation with 2 Gy resulted in a SF2 of 51 %. In
celi eultures with rhKGF, the mean PE was
identical (4.6%). After irradiation with 2 Gy, a
similar SF2 ot 54% was observed, indieating
that KGF did not change the survival
characteristics ot HEKn keratinocytes. Individual
colony size, however, in all cultures ineubated
with rhKGF was significantly increased
compared to incubation without rhKGF. The
number ot extremely large eolonies (D2 mm)
was clearly higher (p=O.OOOO) with rhKGF-
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containing culture medium. In conclusion,
rhKGF does not affect keratinocyte survival after
irradiation, but stimulates proliferation of
surviving cells.
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TOLERANCE OF RAOIOTHERAPY
(3D-CRT) AND ANDROGEN
ABLATION FOR PATIENTS WITH
PROSTATE CANCER
P. Milecki, G. 5tryczyńska, T. 5łachowski,
Z. Kwias, M. Matecka-Nowak
Greatpoland Cancer Center, Poznań, Poland,
Medical University Poznań, Poland
Purpose: evaluation acute tolerance ot
combined treatment (XRT and HT).
Material/methods: Between April 1999 and
September 2000, 22 patients with prostate
cancer (T1-T3NXMO) were treated with 3D-CRT
and HT. Median age of patients was 68
years.EBRT was administered daily traction of
1.8Gy,total dose 70.2Gy. Planning target
volume (PTV) was defined as c1inical target
volume CTV(prostate and seminal vesicles) with
10mm margins around prostate except posterior
margin where 5mm were used to decrease risk
ot rectum morbidity.Acute toxicities were
evaluated using RTOG scoring scale. Median
follow-up was 11 months. Results: Acute etfects
in gastrointestinal tract (Gl) noted were; rectal
discomfort and mild diarrhea. Acute
genitourinary (GU) symptoms included urgency,
nocturia and dysuria. Gl toxicity was observed in
75 % of patients (grade O and 1), and 25% of
patients (grade 2). GU toxicities were as tollow:
grade Oand 1 -80% ot patients) and grade 2 -
(20% ot patients). No grade 3 ar 4 Gl and GU
toxicities were observed. Conclusions:
Preliminary results of treatment with 3D-CRT
suggested that such modality is well tolerated.
HT did not exacerbate radiation toxicity.
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GENETHERAPYOFCANCER
A. Mackiewicz
Dept. of Cancer Immunology, University School
of Medical Sciences and GreatPoland Cancer
Center, Poznań, Poland.
Number of gene therapy clinical triais and
patients enrolled increases exponentially. Today
there are more than 400 triais and over 4000
patients involved all over the world. However,
most of the trails are in the early clinical phases.
34
About 67% of triais are related to cancer. Most
ot the cancer gene therapy strategies are based
on various forms of gene-immunotherapy which
include genetically modified tumor vaccines
(GMTV), direct intratumoral administration of
genes encoding immunostimulatory factors or
insertion of these genes into tumor infiltrating
Iymphocytes (TIL). Other strategies include
suicide gene therapy, direct intratumoral
administration ot genes encoding anti-
oncogenes, gene anti-angiogenic therapy or
bone marrow cells protection against high dose
anti-cancer chemotherapy using MDR genes.
Various gene carries are employed in above
strategies. Retroviral vectors or
Adenoassociated virus vectors are used for
GMTV construction, TIL and bone marrow cells
modifications. Adenoviral vectors and liposomes
are employed tor direct intratumoral gene
administration. Other carriers such as lentiviral
vectors (based on HIV) or SV40 based vectors
are in the preclinical studies.
In January 1996 we have initiated melanoma
gene-immunotherapy clinical trial using GMTV
comprising ot irradiated autologous melanoma
ceUs admixed with ceUs of two allogeneic
melanoma celi lines modified to secrete
interleukin 6 (IL-6) and agonistic soluble IL-6
receptor (sIL-6R). Until now more than 180
patients were enrolled into study. Phase I trail
demonstrated that GMTV is not toxic and
possesses therapeutic potential. Phase II trial
has shown that in melanoma stage IV with
measurable metastatic disease GMTV
significantly extended patients' survival. In 16
out of 45 patients (36%) response to the GMTV
was observed (4 CR, 4 PR and 8 mixed
responses including SD). More than 60% ot
responding patients survived 2 years while none
'ot non-responders survived that period (rank-Iog
test p<O.0001). CD4+/CD8+ T cells ratio,
antibody response, soft tissue metastases and
performance status correlated with c1inical
response. Above results allowed the design ot
the phase III randomized double blind study
which is about to be initiated.
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DO WE GAME ANY BENEFIT FROM
ACCELERATED IN RADIOTHERAPY
FOR HEAD AND NECK TUMOR
CANCER - WEEKEND'S MYSTERY?
B. Maciejewski, H.R. Withers, R. Tarnawski
Centrum Onkologii - Instytut,
Oddział w Gliwicach
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